

## REMARKS

Claims 41, 46, 48, 50, 53, 54, 56, 57, 58, 60, 62, 65, 66, 68 and 70 are currently amended. Claims 49 and 61 are canceled. Reconsideration of the application is requested.

**I: The rejection of claims 41, 46 and 70 under 35 U.S.C. 112 -2<sup>nd</sup> paragraph**

These claims are currently amended. Reconsideration is urged.

**II: The rejection of claims 49, 61, 55 under 35 U.S.C. 112**

Claims 49 and 61 are canceled. Any remaining rejections thereto are moot.

Claim 55 is currently amended. Reconsideration is urged.

**III: The rejection of claims 41, 46-49, 51, 52, 59-61, 63, 64, 66-69 under 35 U.S.C. 102(b)**

Reconsideration is urged in light of the amendments above.

**IV: The rejection of claims 41, 46-65, 66, 67 and 70 under 35 U.S.C. 102(b)**

Reconsideration is urged in light of the amendments above.

**IV. Conclusion**

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Should any additional fees be due the USPTO is authorized to charge the deposit account of Novozymes North America, Inc, *i.e.*, deposit account no. 50-1701.

Respectfully submitted,

Date: August 19, 2011

/Michael W. Krenicky Reg#45411/  
Michael W. Krenicky, Reg. No. 45,411  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(919) 494-3905